Skip to content

Comparison of progressive resistive training on a short arm centrifuge

Comparison of progressive resistive training on a short arm centrifuge - ProGress

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035768
Enrollment
20
Registered
2025-01-10
Start date
2025-03-04
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Interventions

Group 1: SAHC: Centrifuge group 12 weeks in total with 3 one-hour training sessions per week. Squats and calf raises on the short-arm centrifuge Progression of the training weight up to a maximum of 2

Sponsors

DLR – Institut für Luft- und Raumfahrtmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: • Healthy males/females, age 18-45 years • BMI 18-25 • Body height 160 – 190 cm • Recreationally active (approx. 2h training per week) • Successful completion of screening examination • For centrifuge group: Successful completion of SAHC medical

Exclusion criteria

Exclusion criteria: • Additional significant physical exercises during the whole study • Athletes (either professional athletes or more than 4h/week training) • months without strength training • Frequent episodes of kinetosis • Drug or alcohol abuse (regular consumption of 20-30 g alcohol / day) • Any musculoskeletal condition that precludes resistive training • Diabetes mellitus • Herniated disc • Use of psychotropic drugs and any other drugs that may affect the study experiments. • Heart disease or a cardiac pacemaker. • Abnormal blood pressure (above 140/90 mmHg or below 90/60 mmHg) • Severe orthostatic intolerance or impaired neuro-vestibular function. • Contra-indications against biopsy (e.g. impaired hemostasis, keloidosis, history of adverse reactions to local anesthesia or to surgical procedures) • Kidney disease (Deviations from normal values of creatinine in plasma; Creatinine normal value < 1.20 mg / dL *) • Thyroid dysfunction (deviations from normal values for TSH in plasma; normal values TSH 0,27 - 4,20 mU / l *) (*a laboratory examination carried out only in case of suspicion of dysfunction) • Anemia (Hb lower the normal value; standard value Hb men: from 13.5 to 17.5 g / dL) * (*reference values from: http://ilp.charite.de/service/parameter_und_referenzwerte/) • History of epileptic seizures • Chronic back pain • For female test subjects: pregnancy, a pregnancy test is carried out before MRI measurements

Design outcomes

Primary

MeasureTime frame
Muscle volume of m. quadriceps femoris pre-and post a 12-week training period via MRI.

Secondary

MeasureTime frame
• Progression reached during last training session; • MRI: volumes of triceps surae muscles, individual quadriceps muscle heads, glutei muscles and iliopsoas muscles before and after 12 weeks of training; • MRI: Lipid content of all muscles studied including subcutaneous fat and abdominal fat; • MVC: isometric, isokinetic maximum torque of foot plantarflexion and knee extension; • Isometric and isokinetic strength testing; • Quick isokinetic testing; • Surface muscular EMG parameter from various leg and hip muscles (amplitude, pre- innervation time, reaction time, median frequency); • Mechanical performance during training (peak force, peak power, peak ground reaction force, force development, ground contact time); • Jumping mechanography (countermovement jump, 1-leg and 2-leg hopping); • Muscle metabolism and myofiber type-specific analyses via muscle biopsy prior first and after last training session; • Clinical blood chemistry parameters (hormones, lactate etc., from blood samples taken at baseline and after first and last training sessions); • Maximal oxygen uptake (v02max); • Borg-Scale (questionnaire on subjective training effort filled after each session);

Countries

Germany

Contacts

Public ContactLaura de Boni

DLR – Institut für Luft- und Raumfahrtmedizin

laura.deboni@dlr.de02203 601 1021

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026